MBRX Pipeline

IMPORTANT DISCLAIMER

This post is for informational and educational purposes only. It is NOT financial, investment, or trading advice. I am not a registered investment advisor, broker, or financial professional. Nothing here constitutes a recommendation to buy, sell, or hold any security, including MBRX. Investing in stocks, especially small-cap biotechs, involves a high degree of risk and can result in the complete loss of your investment. Past performance or recent news is no guarantee of future results. Always do your own research (DYOR), consider your risk tolerance, and consult a licensed financial advisor before making any investment decisions. Trade at your own risk—I will not be held liable for any losses.

MBRX Breakout Alert: Moleculin Biotech's MIRACLE Trial Data Sparks 10%+ Surge – Should You Jump In?

February 18, 2026 | By Shane Shipman (@shaneman007)

Hey everyone, if you're like me—scanning for those explosive small-cap biotechs—you probably felt that rush this morning watching MBRX (Moleculin Biotech) pop. The stock is up around 10%+ today (hitting highs near $5.00–$5.14 in recent action after closing at $4.56 yesterday), and volume is picking up. That "nervous excitement" vibe? Totally get it. Part of you wants to hit buy, the other part remembers how fast these can reverse.

The Catalyst: Fresh MIRACLE Trial Data Drops

Moleculin just released preliminary blinded data from their pivotal Phase 2B/3 MIRACLE trial testing Annamycin + cytarabine in relapsed/refractory acute myeloid leukemia (R/R AML). Key highlights:

  • 40% composite complete remission (CRc) rate in the first 30 subjects (30% full CR + 10% CR with partial hematological recovery).
  • That's a 67% improvement over historical response rates with cytarabine alone.
  • They've treated 35 subjects so far, with another 11 in screening/identified—on track to hit the first milestone of 45 subjects in Q1 2026.
  • First data unblinding expected after that (late Q2 2026 for the initial arm), with no cardiotoxicity seen in safety data to date (huge for anthracyclines).
  • Roughly 35% of subjects are venetoclax failures—tough population where options are limited.

This is the kind of early efficacy signal that can ignite a micro-cap biotech (market cap still tiny ~$14M). It's not final locked data yet—preliminary and blinded—but it's enough to get the momentum crowd excited. (Again, this summary is just sharing public info—NOT advice to act on it.)

Technical Setup: Breakout in Play?

On the chart side, MBRX has been coiling near lows (52-week range $3.13–$55.50, with that high likely pre-adjustments). Today's push above recent resistance (~$4.70–$5.00 area) on rising volume feels like a classic breakout attempt. Some scanners are flashing "strong buy" on moving averages and indicators right now.

Watch these levels:

  • Upside confirmation: Hold above $5.00–$5.14 highs with volume.
  • Support on pullback: Around $4.50–$4.70 (yesterday's close/action zone).

Biotechs can run hard on news like this, but they fade just as fast on profit-taking or dilution fears. Charts and momentum are interesting to watch, but they're not predictions.

The Risk Side (Because We're Not Blind Bulls)

Look, small-cap biotechs are gambling territory—high risk of significant or total loss:

  • Data is preliminary—could change with full unblinding/audits.
  • Micro-cap = extreme volatility, potential dilution if they need cash.
  • Full approval path is still long (more data in 2026).
  • Investing/trading involves substantial risk; you could lose more than you invest.

If you're feeling that "kind of want to get in, kind of nervous" pull like I am, consider:

  • Small position size—spec play only (if you decide to play at all).
  • Scale in on dips if it holds support—but only with money you can afford to lose.
  • Set stops and take partial profits on spikes.
  • Wait for more confirmation (volume + higher highs) if you're risk-averse.

Do your own due diligence and never invest based solely on a blog post, tweet, or news headline.

Bottom Line

MBRX looks like it's at a potential inflection point thanks to solid early MIRACLE data. The setup has breakout written all over it, but biotechs don't hand out free wins. This is just one trader's take on public info and charts—purely for discussion and entertainment.

What about you? Jumping in today, waiting for pullback, or sitting it out? Drop your thoughts in the comments—let's discuss! (But remember: your decisions are yours alone.)

NOT FINANCIAL ADVICE. For informational purposes only. No guarantees, express or implied. Trading stocks involves high risk of loss. Always consult a qualified professional. Follow for more small-cap biotech setups: @shaneman007 on X

Comments

Post a Comment

Popular posts from this blog

ZKIN I'm Inn

Is ZKIN the Next Big Swing Trade Opportunity? Technical Analysis and Trade Plan (I generated this blog post from the Sleep Inn Oklahoma City Bricktown with the help of Grok accuracy is not guaranteed) ZK International Group Co., Ltd. (NASDAQ: ZKIN) is catching the eye of swing traders with its recent price action, high volatility, and potential catalysts. Priced at $1.88 (as of August 19, 2025), ZKIN offers a compelling setup for traders looking to capitalize on short-term price swings. This blog post dives into the technical and fundamental factors driving this opportunity, outlines two trade setups, and provides a step-by-step guide to execute them. Click the dropdowns for deeper insights! Why ZKIN? The Opportunity at a Glance ZKIN, a small-cap stock with a $9.71M market cap, operates in the steel and cryptocurrency sectors, with recent developments like a Shenzhen Gas Group contract and the upcoming xSigma Wallet launch fueling optimism. ...
Read more

WULF Moderate Risk High Potential For Return

TeraWulf Inc. (WULF): A Swing Trading Opportunity with 30% Chance of 60% Return Date: July 29, 2025 | Stock Price: $5.19 | Market: NASDAQ Grok assisted blog accuracy not guaranteed  Research suggests TeraWulf Inc. (WULF) offers a compelling swing trading opportunity, with a 30% chance of achieving a 60% return , potentially reaching $8.30 from its current price of $5.19. This potential is driven by upcoming earnings, Bitcoin market trends, and the company’s strategic pivot to high-performance computing (HPC) hosting. Here’s a detailed breakdown for swing traders looking to capitalize on this high-risk, high-reward stock. Stock Overview TeraWulf Inc., a Technology Services company in the Data Processing Services sector, is a Bitcoin miner transitioning to HPC hosting for AI and cloud computing. Trading at $5.19 as of 10:35 AM CDT on July 29, 2025, WULF has a 52-week range of $2.06–$9.30, reflecting its vol...
Read more

INHD Inhibikase Therapeutics

INHD Swing Trade Setup: High-Reward Opportunity for Aggressive Traders Posted on August 29, 2025 Grock assisted log accuracy not guaranteed Hey traders! If you’re looking for a high-octane swing trade with big potential, Inhibikase Therapeutics (INHD) might be your next play. Inspired by momentum-driven traders like @TigerLineTrades and recent buzz on X (like @timothysykes calling out INHD’s spike from $2.60s to $3.80s), I’ve put together an aggressive swing trade setup targeting 30–90% returns in just 1–3 days. Here’s the breakdown, complete with entry points, exit targets, and key indicators to watch. Let’s dive in! Why INHD? The Setup Explained INHD, a clinical-stage biotech, is making waves with its work on Parkinson’s and pulmonary arterial hypertension (PAH). Recent catalysts, like FDA approval for a late-stage PAH trial and $275M in financing (August 2025), have fueled volatility—perfect for swing traders chasing quick gains. With a recent ...
Read more